Asia
Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
Bloomberg noted that Takeda’s CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus.
Teva’s stock jumped as investors get more hopeful about the future.
In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results.
The financing was led by Zhonguancun Development Group and Shanghai Creation Investment Management.
The company sold the stake to Sapphire I Holdings at an undisclosed price.
Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
Ark will be responsible for preclinical and clinical development of the molecule.
Teva continues to be battered by its massive debt load and struggling pipeline.
The PE firm made the investment just three years ago.
PRESS RELEASES